Secreted glycoprotein that binds and neutralizes myostatin (GDF-8), activin A and B, and BMP-2/4. Multiple binding sites with very high affinity neutralize multiple TGF-β superfamily inhibitors of muscle growth simultaneously. The 344 isoform has distinct heparin-binding characteristics vs 288 isoform.
Studies have administered: Research phase only; gene therapy vectors more studied; injectable pharmacology limited data
Animal models: 200–300% muscle mass increase with gene therapy expression. Exogenous protein: meaningful but more modest effects. Human gene therapy trial (Lee, 2014): increased muscle mass in muscular dystrophy patients. Direct peptide injection human data sparse.
Limited human pharmacokinetic safety profile available; theoretical concern of off-target activin/BMP pathway modulation in non-muscle tissues
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Follistatin-344 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat